ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.522,46
-0,42%
S&P 500
5.631,22
0,28%
Dow Jones
40.211,72
0,53%
Euro vs US Dollar
1,09013
0,02%
Bitcoin
63.464,54
-2,14%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) News

VRDN

Viridian Therapeutics (VRDN)

Viridian Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:VRDN
DatumZeitQuelleÜberschriftSymbolFirma
30/10/202313h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
30/10/202313h30Business WireViridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement FinancingNASDAQ:VRDNViridian Therapeutics Inc
26/10/202314h00Business WireViridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye DiseaseNASDAQ:VRDNViridian Therapeutics Inc
25/09/202322h35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
25/09/202322h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
25/09/202314h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
25/09/202314h00Business WireViridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of DirectorsNASDAQ:VRDNViridian Therapeutics Inc
19/09/202322h30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VRDNViridian Therapeutics Inc
12/09/202322h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
07/09/202314h00Business WireViridian Therapeutics Announces Presentations at Multiple Medical Meetings in SeptemberNASDAQ:VRDNViridian Therapeutics Inc
08/08/202323h21Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VRDNViridian Therapeutics Inc
08/08/202322h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VRDNViridian Therapeutics Inc
08/08/202322h01Business WireViridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
04/08/202322h01Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:VRDNViridian Therapeutics Inc
24/07/202322h06Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:VRDNViridian Therapeutics Inc
17/07/202313h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
11/07/202314h56IH Market NewsTuesday’s Wall Street Highlights: Amazon, Better Therapeutics, Blackstone, Microsoft and moreNASDAQ:VRDNViridian Therapeutics Inc
10/07/202323h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VRDNViridian Therapeutics Inc
10/07/202322h01Business WireViridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)NASDAQ:VRDNViridian Therapeutics Inc
06/07/202322h05Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)NASDAQ:VRDNViridian Therapeutics Inc
20/06/202323h23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
17/06/202301h52Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VRDNViridian Therapeutics Inc
13/06/202314h00Business WireViridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine SocietyNASDAQ:VRDNViridian Therapeutics Inc
05/06/202322h05Business WireViridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
09/05/202322h11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:VRDNViridian Therapeutics Inc
09/05/202322h01GlobeNewswire Inc.Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:VRDNViridian Therapeutics Inc
08/05/202314h00GlobeNewswire Inc.Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable InjectionsNASDAQ:VRDNViridian Therapeutics Inc
04/05/202322h05GlobeNewswire Inc.Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:VRDNViridian Therapeutics Inc
02/05/202314h00GlobeNewswire Inc.Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023NASDAQ:VRDNViridian Therapeutics Inc
28/04/202314h29Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:VRDNViridian Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VRDN

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
TG
432
Arbor Metals
USOTC
BNPQY
BNP Paribas (QX)
NYSE
MRK
Merck
TG
ALV
Allianz
COIN
SOLUSD
Solana
NASDAQ
GOOGL
Alphabet
COIN
ETHUSD
Ethereum
NASDAQ
AMZN
Amazon.com
NYSE
MCD
McDonalds
TG
D7G
Nel ASA
USOTC
ADDYY
Adidas (QX)
COIN
BTCUSD
Bitcoin
DBI
DAX
DAX
AMEX
SPY
SPDR S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten